MDRNA Sells Manufacturing Business to Par Pharmaceuticals to Hone RNAi Focus

The agreement, which eliminates all of MDRNA's non-RNAi expenses, "represents the final step in our plan to create a company solely focused in the research and development of RNAi-based therapeutics," Michael French, president and CEO of MDRNA, said in a statement.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.